Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

141. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review Full Text available with Trip Pro

Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Psychological treatments may offer limited clinical benefit in improving HbA1c for adults with type 2 diabetes, but there was no benefit in adults or children with type 1 diabetes. {{author}} {{($index , , , , , , & . Kirsty Winkley 1, * , Rebecca Upsher 2 , Daniel Stahl 3 , Daniel Pollard 4 , Architaa Kasera 2 , Alan Brennan 4 , Simon Heller 5 , Khalida Ismail 2 1 Florence Nightingale Faculty of Nursing

2020 NIHR HTA programme

142. Type 1 and Type 2 diabetes and COVID-19 related mortality in England

Type 1 and Type 2 diabetes and COVID-19 related mortality in England NHS England » Type 1 and Type 2 diabetes and COVID-19 related mortality in England Cookies on the NHS England and NHS Improvement website We’ve put some small files called cookies on your device to make our site work. We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site. Let us know if this is OK. We’ll use (...) a cookie to save your choice. You can before you choose. Change my preferences I'm OK with analytics cookies Search Search Menu . If you are a member of the public looking for health advice, go to the . And if you are looking for the latest travel information, and advice about the government response to the outbreak, go to the . Type 1 and Type 2 diabetes and COVID-19 related mortality in England Document first published: 20 May 2020 Page updated: 19 May 2020 Topic: , Publication type: Document PDF 497

2020 NHS England

143. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial Full Text available with Trip Pro

) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial , , , , , , , , , Affiliations Expand Affiliations 1 Children's Hospital AUF DER BULT, Hannover Medical School, Hannover, Germany danne@hka.de. 2 Department of Pediatrics, Yale University School of Medicine, New Haven, CT. 3 Department of Pediatrics, Bashkir State Medical University, Ufa, Russian Federation. 4 CPCLIN Clinical Research Center, São Paulo, Brazil. 5 Department (...) Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial - PubMed This site needs JavaScript

2020 EvidenceUpdates

144. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial

Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology (...) Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Aug;43(8):1822-1828. doi: 10.2337/dc20-0124. Epub 2020 May 29. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial , , , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators iDCL Trial Research Group

2020 EvidenceUpdates

145. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial

Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation JAMA Surg Actions . 2020 Jun 3;e200420. doi: 10.1001/jamasurg.2020.0420. Online ahead of print. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial , , , , , , , , , , , , , , , , , , Affiliations Expand

2020 EvidenceUpdates

146. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial Full Text available with Trip Pro

, University of Dundee, Dundee DD1 9SY, UK. 2 Department of Medical Physics, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK. 3 Department of Radiology, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK. PMID: 32578850 DOI: Item in Clipboard A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial Alexander J M Brown et al. Eur Heart J . 2020 . Show details Eur Heart J Actions . 2020 Jun 24;ehaa419. doi: 10.1093 (...) may regress left ventricular hypertrophy (LVH) in people with type 2 diabetes (T2D). Methods and results: We randomly assigned 66 people (mean age 67 ± 7 years, 38 males) with T2D, LVH, and controlled blood pressure (BP) to receive dapagliflozin 10 mg once daily or placebo for 12 months. Primary endpoint was change in absolute left ventricular mass (LVM), assessed by cardiac magnetic resonance imaging. In the intention-to-treat analysis, dapagliflozin significantly reduced LVM compared

2020 EvidenceUpdates

147. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. Full Text available with Trip Pro

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease.In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter (...) , an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m2 of body-surface area, and evidence of diabetic kidney disease to receive allopurinol or placebo. The primary outcome was the baseline-adjusted GFR, as measured with iohexol, after 3 years plus a 2-month washout period. Secondary outcomes included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate after washout. Safety was also assessed.A total of 267 patients were assigned to receive allopurinol and 263 to receive

2020 NEJM

148. A juxtaposition of safety outcomes between various doses of sodium-glucose co-transporter inhibitors, in insulin-treated type-1 diabetes mellitus patients: a protocol for systematic review and meta-analysis of double-blinded randomized controlled trials. Full Text available with Trip Pro

A juxtaposition of safety outcomes between various doses of sodium-glucose co-transporter inhibitors, in insulin-treated type-1 diabetes mellitus patients: a protocol for systematic review and meta-analysis of double-blinded randomized controlled trials. A juxtaposition of safety outcomes between various doses of sodium-glucose co-transporter inhibitors, in insulin-treated type-1 diabetes mellitus patients: a protocol for systematic review and meta-analysis of double-blinded randomized (...) controlled trials | medRxiv Search for this keyword A juxtaposition of safety outcomes between various doses of sodium-glucose co-transporter inhibitors, in insulin-treated type-1 diabetes mellitus patients: a protocol for systematic review and meta-analysis of double-blinded randomized controlled trials Sumanta Saha doi: https://doi.org/10.1101/2020.06.22.20137349 Sumanta Saha 1 None For correspondence: ABSTRACT Aims Several clinical trials have tested the safety profile of sodium-glucose co-transport

2020 Cold Spring Harbor Laboratory

149. Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled Trials Full Text available with Trip Pro

Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled Trials Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled Trials | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has (...) not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Original investigation Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled

2020 Research Square

150. Bone Health in the Elderly with Type 2 Diabetes Mellitus–A Systematic Review Full Text available with Trip Pro

; bone structure; bone turnover; fractures 1. Introduction The average human lifespan has increased by 5.5 years over the last 16 years [ ]. Currently, the average life expectancy in Europe and the United States of America is 80.9 years and 78.7 years, respectively, with the highest life expectancy reported in women [ , ]. Consequently, the need for effective prevention and treatment of chronic aging-related diseases has increased. Type 2 diabetes mellitus (type 2 DM; T2DM) and osteoporosis are two (...) Bone Health in the Elderly with Type 2 Diabetes Mellitus–A Systematic Review OBM Geriatrics | Bone Health in the Elderly with Type 2 Diabetes Mellitus–A Systematic Review Welcome to LIDSEN Publishing Inc. or OBM Geriatrics Quick Link (ISSN 2638-1311) OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical

2020 OBM Geriatrics

151. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. Adolescents and young adults with type 1 diabetes exhibit the worst glycemic control among individuals with type 1 diabetes across the lifespan. Although continuous glucose monitoring (CGM) has been shown to improve glycemic control in adults, its benefit in adolescents and young adults has not been demonstrated.To determine the effect of CGM on glycemic (...) control in adolescents and young adults with type 1 diabetes.Randomized clinical trial conducted between January 2018 and May 2019 at 14 endocrinology practices in the US including 153 individuals aged 14 to 24 years with type 1 diabetes and screening hemoglobin A1c (HbA1c) of 7.5% to 10.9%.Participants were randomized 1:1 to undergo CGM (CGM group; n = 74) or usual care using a blood glucose meter for glucose monitoring (blood glucose monitoring [BGM] group; n = 79).The primary outcome was change

2020 JAMA

152. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. Continuous glucose monitoring (CGM) provides real-time assessment of glucose levels and may be beneficial in reducing hypoglycemia in older adults with type 1 diabetes.To determine whether CGM is effective in reducing hypoglycemia compared with standard blood glucose monitoring (BGM) in older adults with type 1 diabetes.Randomized clinical trial conducted at 22 (...) ); and cognition and patient-reported outcomes, with adjustment for multiple comparisons to control for false-discovery rate.Of the 203 participants (median age, 68 [interquartile range {IQR}, 65-71] years; median type 1 diabetes duration, 36 [IQR, 25-48] years; 52% female; 53% insulin pump use; mean HbA1c, 7.5% [SD, 0.9%]), 83% used CGM at least 6 days per week during month 6. Median time with glucose levels less than 70 mg/dL was 5.1% (73 minutes per day) at baseline and 2.7% (39 minutes per day) during

2020 JAMA

153. Vitamin D receptor gene polymorphisms and the risk of the type 1 diabetes: a meta-analysis based on 40 case–control studies Full Text available with Trip Pro

a significant association between VDR gene polymorphism and T1DM susceptibility in ethnic-specific analysis. Keywords Vitamin D receptor; Type 1 diabetes mellitus; polymorphism; meta-analysis Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 1. Background 2. Methods 3. Results 4. Discussion 5. Conclusion Abbreviations Declarations References Tables Supplementary Files This is a list of supplementary files associated with this preprint. Click to download. Comments (0) Comments can take the form (...) Vitamin D receptor gene polymorphisms and the risk of the type 1 diabetes: a meta-analysis based on 40 case–control studies Vitamin D receptor gene polymorphisms and the risk of the type 1 diabetes: a meta-analysis based on 40 case–control studies | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review

2020 Research Square

154. GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis Full Text available with Trip Pro

GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis 切换导航 切换导航 Search Open Access Meta-Analysis GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis Affiliation: Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda (...) option for NAFLD or NASH. Keywords Glucagon-like peptide-1 receptor agonists, type 2 diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis Introduction Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease that includes a variety of progressive pathologic conditions, spanning from simple steatosis to steatohepatitis (NASH), advanced fibrosis and, lastly, cirrhosis [ , ]. To date, NAFLD is an increasingly recognized public health problem worldwide, affecting

2020 Exploration of Medicine

155. Metformin monotherapy for adults with type 2 diabetes mellitus. Full Text available with Trip Pro

Metformin monotherapy for adults with type 2 diabetes mellitus. Worldwide, there is an increasing incidence of type 2 diabetes mellitus (T2DM). Metformin is still the recommended first-line glucose-lowering drug for people with T2DM. Despite this, the effects of metformin on patient-important outcomes are still not clarified.To assess the effects of metformin monotherapy in adults with T2DM.We based our search on a systematic report from the Agency for Healthcare Research and Quality (...) , and topped-up the search in CENTRAL, MEDLINE, Embase, WHO ICTRP, and ClinicalTrials.gov. Additionally, we searched the reference lists of included trials and systematic reviews, as well as health technology assessment reports and medical agencies. The date of the last search for all databases was 2 December 2019, except Embase (searched up 28 April 2017).We included randomised controlled trials (RCTs) with at least one year's duration comparing metformin monotherapy with no intervention, behaviour

2020 Cochrane

156. Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China Full Text available with Trip Pro

Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China Toggle navigation Collaborations Publish Now Registrations Manuscript Guidelines Other Services Policies Policies ISSN: 2455-8583 Research Article Open Access Peer-Reviewed Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes (...) diabetes; Microvascular complications; Prevalence; Systematic review; Meta-analysis; Meta-regression Cite this as Cheng Y, Qu S, Liu Y, Zhang Y, Xu W, Chen L, et al. (2020) Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China. Glob J Obes Diabetes Metab Syndr 7(2): 018-023. DOI: Objective: This study aims to estimate the overall prevalence of microvascular complications of type 2 diabetes in mainland China, and to identify any associated risk

2020 Global Journal of Obesity, Diabetes and Metabolic Syndrome

157. The association between various biological, behavioural and psychosocial factors and type 2 diabetes mellitus in Africa: a systematic review and meta-analysis Full Text available with Trip Pro

The association between various biological, behavioural and psychosocial factors and type 2 diabetes mellitus in Africa: a systematic review and meta-analysis The association between various biological, behavioural and psychosocial factors and type 2 diabetes mellitus in Africa: a systematic review and meta-analysis | Research Square Browse Tools & Services Your Cart This preprint is under consideration at BMC Public Health . A preprint is a preliminary version of a manuscript that has (...) not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article The association between various biological, behavioural and psychosocial factors and type 2 diabetes mellitus in Africa: a systematic review and meta-analysis Ayuba Issaka, Yin Paradies

2020 Research Square

158. Vitamin D receptor gene polymorphisms and the risk of the Type 1 diabetes: A meta-regression and updated meta-analysis  Full Text available with Trip Pro

association between VDR gene polymorphism and T1DM susceptibility in ethnic-specific analysis. Keywords Vitamin D receptor; Type 1 diabetes mellitus; polymorphism; meta-analysis Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 1. Background 2. Methods 3. Results 4. Discussion 5. Conclusion Abbreviations Declarations References Tables Supplementary Files This is a list of supplementary files associated with this preprint. Click to download. Comments (0) Comments can take the form of short (...) Vitamin D receptor gene polymorphisms and the risk of the Type 1 diabetes: A meta-regression and updated meta-analysis  Vitamin D receptor gene polymorphisms and the risk of the Type 1 diabetes: A meta-regression and updated meta-analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review

2020 Research Square

159. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association

Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site (...) uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association , MD, MHA, Chair , MD, MPH, FAHA, Vice Chair , MD, FAHA , MD , MD , MD , MD, FAHA , MD, FAHA , MD, MHS , MD, MPH, FAHA , MD, FAHA Suzanne V. Arnold , Deepak L. Bhatt , Gregory W. Barsness , Alexis L

2020 American Heart Association

160. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Full Text available with Trip Pro

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Dose-response, Efficacy, and Safety of Oral Semaglutide Monotherapy in Japanese Patients With Type 2 Diabetes (PIONEER 9): A 52-week, Phase 2/3a, Randomised, Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2020 May;8(5):377-391. doi: 10.1016/S2213-8587(20)30075-9. Dose-response, Efficacy, and Safety of Oral Semaglutide Monotherapy in Japanese Patients With Type 2 Diabetes (PIONEER 9): A 52-week, Phase 2/3a, Randomised, Controlled Trial

2020 EvidenceUpdates